Objective: To assess the pharmacokinetics and safety of liquid palivizumab compared with lyophilized palivizumab. Methods: This phase 2, randomized, doubleblind crossover study included premature infants aged B6 months born B35 weeks gestational age. Patients were randomized in a 1:1 ratio to receive a single 15 mg/kg intramuscular dose of liquid (sequence A group) or lyophilized (sequence B group) palivizumab on Day 0. Patients crossed over to receive the alternate formulation on Day 30. Serum palivizumab and antidrug antibody (ADA) levels were measured on Day 0 (predose), Day 30 (before the dose of alternate formulation), and Day 60 (30 days after the dose of alternate formulation). Patients were followed for safety through Day 60 (30 days after the dose of alternate formulation). Results: A total of 153 infants were randomized into the study (sequence A 75; sequence B 78). Sequence A and sequence B trough serum palivizumab levels were similar on Day 30 (51.7
INTRODUCTION
Respiratory syncytial virus (RSV) is a viral pathogen that is a common cause of acute lower respiratory infection in infants and children worldwide [1] . By 2 years of age, most children have been infected with RSV at least once [2] . The risk for severe RSV is particularly high in children who were born prematurely, or who have congenital heart disease (CHD), or chronic lung disease of prematurity (CLDP) [2] .
In 2005, it was estimated that there were 33.8 million cases of RSV-associated acute lower respiratory infection worldwide in children\5 years of age [1] . Of these, 3.4 million were severe and required hospitalization, and 66,000-199,000 cases resulted in death [1] .
Respiratory syncytial virus immune globulin (RespiGam, MedImmune, Gaithersburg, MD, USA) was the first RSV-specific prevention used in high-risk infants [3] . Although this therapy was effective, it required several hours of an intravenous (IV) infusion [3] . Palivizumab (MedImmune, Gaithersburg, MD, USA), an F-protein-specific humanized monoclonal antibody, was the first monoclonal antibody developed to prevent an infectious disease and represented an advance in RSV prevention. Palivizumab was approved by the Food and Drug Administration (FDA) in 1998 and is indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk for RSV disease [3] . In addition, palivizumab offers a more convenient, intramuscular (IM), route of administration [4] . Palivizumab was first manufactured as a lyophilized powder [5] . Lyophilized palivizumab is administered at a dose of 15 mg/kg IM monthly throughout the RSV season [4] . The efficacy of lyophilized palivizumab is well established; results from three randomized, placebo-controlled studies have shown that palivizumab resulted in a 45-82% reduction in RSV hospitalizations [6] [7] [8] . However, lyophilized palivizumab requires reconstitution with sterile water, which takes approximately 20 min, and the drug must be used within 6 h of reconstitution [5] . A liquid formulation of palivizumab bypasses the need for reconstitution and simplifies the administration of palivizumab. This liquid formulation was approved by the FDA in 2004 based, in part, on the results of this study [5] , and has been the only formulation distributed in the United States since 2006. The reduced time required for administration of liquid versus lyophilized palivizumab has additional clinical relevance in that it enables high-risk infants to spend less time in a healthcare provider's waiting room, thereby decreasing their exposure to other sick children visiting the pediatrician. Single-dose pharmacokinetics (PK) and safety profile of the liquid formulation of palivizumab administered IV and IM were first tested and compared with the lyophilized formulation in 53 healthy adult volunteers. In this parallel cohort study, liquid palivizumab demonstrated PK and safety profiles similar to those of lyophilized palivizumab [9] .
The goal of the current study was to establish bioequivalence and safety of the liquid formulation in a pediatric population for whom palivizumab is approved. This randomized, crossover study assessed the PK, safety, and tolerability of the liquid formulation compared with the lyophilized formulation of palivizumab in infants B6 months of age who were born B35 weeks gestational age. 
METHODS

Patients
Antidrug Antibodies
Serum samples for determining antidrug antibodies (ADA) to palivizumab from patients who had previously consented to additional testing were collected at baseline and on study Days 30 and 60. ADA assays were performed with the qualified assay described in previous 
Statistical Analyses
The PK analysis included all patients receiving two full doses of study drug, without major protocol violations, and for whom the study visits occurred within the specified visit windows. All patients who received study drug were included in the safety summaries.
An enrollment goal of 60 per sequence group was initially calculated based on estimates of between-patient and within-patient variability obtained from previous studies, and was calculated to yield an 80% chance that the 90% confidence interval (CI) of the within-patient standard deviations (SD) of the log trough concentration would be between 0.80 and 1.25.
The sample size was increased to 75 because of potential difficulties in obtaining adequate blood samples from infants, and to allow for withdrawals and dropouts in the study. 
RESULTS
Patients
A total of 153 patients were randomized into the study (75 to sequence A, 78 to sequence B), and 152 completed the study through 30 days after the second injection of the study drug.
One infant in the sequence B group did not complete the study as their parents withdrew consent after the first study drug injection.
Generally, demographic and baseline characteristics were similar between the sequence A and sequence B groups (Table 1) .
Pharmacokinetics
The trough serum palivizumab levels on study Days 30 and 60 were similar in both sequence groups. The geometric mean trough serum palivizumab levels obtained on study Day 30 were 51.7 lg/mL in the sequence A group Fig. 2 . Using an ANOVA model, the ratio of the geometric means of the C trough for each formulation was 1.040 and its associated 90% CI was 0.998-1.083, which was within the bioequivalence limits of 0.8-1.25 ( Table 2 ). The results of the ANOVA detected a significant period effect, as expected, due to accumulation of concentrations after the second dose; however, the ANOVA did not detect a statistically significant formulation or sequence effect, indicating no evidence of a differential carryover effect between the 2 sequences. Analyzed as a parallel study (Table 2) , the ratio of the geometric means of the Day 30 C trough was 1.051 (90% CI 0.963-1.148), which was also within the bioequivalence limits of 0.8-1.25.
Safety
Overall, 50.0% (76/152) of infants receiving liquid palivizumab and 49.0% (75/153) receiving lyophilized palivizumab experienced C1 AE from study Days 0-60. The AEs were generally similar between the two groups, and the most common AEs overall were typical for the population of infants B6 months of age with a history of prematurity ( Table 3 ). The proportion of infants with C1 AE reported during each of the Day 0-30 and 30-60 study periods was similar between the liquid and lyophilized palivizumab groups (Table 4) (Table 5 ). Generally, SAEs were similar between the liquid and lyophilized palivizumab groups and were also similar after each injection in both the sequence A and B groups ( Table 5 ). None of Based on the similarity in palivizumab PK between the two formulations in the exploratory study in adults, our current study was designed to evaluate bioequivalence with respect to serum concentrations and to assess similarity in safety between liquid and lyophilized formulations in children at high risk for RSV disease. A crossover design was used since this allows for the assessment of bioequivalence while minimizing the impact of subject-to-subject variability on the results of the analysis. Given that palivizumab is administered monthly in infants, serum trough concentrations were used to assess similarity in palivizumab exposures between lyophilized and liquid formulations in a crossover fashion.
An analysis of palivizumab PK across 22 studies (including data from the current study)
[12] showed that body weight impacts palivizumab exposure, and gestational age Findings from this study of infants aged B6 months with a history of prematurity of B35 weeks gestation showed that liquid and lyophilized palivizumab formulations exhibit comparable PK and similar safety profiles. Similar trough palivizumab levels were observed between the two sequence groups and the 90% CIs for the ratios of least squares geometric means of trough levels for the two formulations were within the 90% confidence limits for bioequivalence.
The half-life of palivizumab is approximately 20 days; palivizumab accumulation is expected upon redosing on Day 30 based on the frequency of dosing compared with the halflife. The trough serum palivizumab levels in the present study were generally consistent with the setting. In the current study, a similar incidence Moreover, the geometric mean ratio and 
